Open Access

Prognostic value of delta‑like protein 3 combined with thyroid transcription factor‑1 in small‑cell lung cancer

  • Authors:
    • Li‑Xu Yan
    • Yan‑Hui Liu
    • Zhi Li
    • Dong‑Lan Luo
    • Yu‑Fa Li
    • Jing‑Hai Yan
    • Jia‑Tao Zhang
    • Chao Liu
    • Xun‑Hua Liu
    • Jiao He
  • View Affiliations

  • Published online on: June 27, 2019     https://doi.org/10.3892/ol.2019.10538
  • Pages: 2254-2261
  • Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rovalpituzumab tesirine is a promising delta‑like protein 3 (DLL3)‑targeted antibody‑drug conjugate for the treatment of small‑cell lung cancer (SCLC). Thyroid transcription factor‑1 (TTF‑1) and DLL3 protein are associated with SCLC, and may be used to identify patients, who respond to the DLL3‑targeted therapy. However, little is known about the expression pattern of the DLL3 protein, and the prognostic value of DLL3 and TTF‑1 for SCLC. A total of 335 patients with SCLC were identified, including 11 patients with paired biopsy of primary site and lobectomy specimens, and 37 patients with paired specimens of primary and metastatic site. The DLL3 expression levels of individuals were evaluated using the anti‑DLL3 antibody. No differences in DLL3 expression levels were observed in paired biopsy and lobectomy specimens (P=0.774), and paired primary and metastatic sites (P=0.472). SCLC cases with high DLL3 expression levels were more frequent in male patients (P=0.041), smokers (P=0.023) and patients with positive TTF‑1 expression (P=0.006) compared with DLL3‑low SCLC. DLL3‑high SCLC exhibited worse overall survival compared with DLL3‑low SCLC (log‑rank test, P=0.007). Patients with TTF‑1+ SCLC experienced a significantly worse overall survival compared with patients with TTF‑1‑ SCLC (P<0.001). DLL3‑low/TTF‑1‑ was defined as a distinct molecular subgroup of SCLC with optimal prognosis (P<0.001). DLL3‑low/TTF‑1‑ was an independent prognostic marker for SCLC (P=0.001). In conclusion, the present study, to the best of our knowledge, provided novel evidence for SCLC intratumoral and intertumoral homogeneity with the identification of DLL3 protein levels. Therefore, it is reliable to use biopsy specimens to evaluate DLL3 expression levels for identification of patients who may benefit from DLL3‑targeted therapy. In addition, DLL3 and TTF‑1 are two protein markers with potential clinical value in risk stratification for patients with SCLC.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yan, L., Liu, Y., Li, Z., Luo, D., Li, Y., Yan, J. ... He, J. (2019). Prognostic value of delta‑like protein 3 combined with thyroid transcription factor‑1 in small‑cell lung cancer. Oncology Letters, 18, 2254-2261. https://doi.org/10.3892/ol.2019.10538
MLA
Yan, L., Liu, Y., Li, Z., Luo, D., Li, Y., Yan, J., Zhang, J., Liu, C., Liu, X., He, J."Prognostic value of delta‑like protein 3 combined with thyroid transcription factor‑1 in small‑cell lung cancer". Oncology Letters 18.3 (2019): 2254-2261.
Chicago
Yan, L., Liu, Y., Li, Z., Luo, D., Li, Y., Yan, J., Zhang, J., Liu, C., Liu, X., He, J."Prognostic value of delta‑like protein 3 combined with thyroid transcription factor‑1 in small‑cell lung cancer". Oncology Letters 18, no. 3 (2019): 2254-2261. https://doi.org/10.3892/ol.2019.10538